✦ LIBER ✦

Exemestane: additional benefits over tamoxifen?

Book ID: 120842363
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816580-00039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Endometrial safety of cross-over treatme

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane

✍ D.G. Kieback; N. Harbeck; W. Bauer; P. Hadji; G. Weyer; A. Hasenburg 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Specific Adverse Events Predict Survival

Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis

✍ Fontein, D. B. Y.; Seynaeve, C.; Hadji, P.; Hille, E. T. M.; van de Water, W.; P 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 290 KB

Efficacy benefit of PEG-DOX not improved

Efficacy benefit of PEG-DOX not improved by addition of tamoxifen

📂 Article 📅 2004 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Warfarin: no additional benefit over asp

Warfarin: no additional benefit over aspirin alone post-MI

📂 Article 📅 1997 🏛 Adis International Limited (now part of Wolters Kl ⚖ 118 KB

There appears to be no additional benefi

There appears to be no additional benefit of continuing adjuvant tamoxifen therapy beyond 5 years

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Sotolol confers no additional benefit ov

Sotolol confers no additional benefit over beta-blockers in post-coronary artery bypass atrial fibrillation

✍ A.K. Woodend; G. Nichol; C.Y. Carey; A.S.L. Tang 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 145 KB